Regeneron: Driven by Science

For over 25 years, Regeneron's vision has been to build an innovative company that consistently brings new medicines to patients with serious diseases.

Recent News

Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016


TARRYTOWN, N.Y. and PARIS, Aug. 29, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholester...

Read more

Upcoming Events

36th Annual Canaccord Genuity Growth Conference

08/11/16 at 11:30 AM ET

View Event

Regeneron Pharmaceuticals Q2 2016 Earnings Conference Call

08/04/16 at 8:30 AM ET

View Event

Form content here please :)